• Home
  • Featured
  • The Best
  • News
  • Reviews
  • Promoted
AndroidGuys
No Result
View All Result
No Result
View All Result
AndroidGuys
No Result
View All Result

FDA Approves Flow Neuroscience’s At-Home Depression Treatment

Jude Chukwuemeka by Jude Chukwuemeka
December 13, 2025
in News
FDA Approves Flow Neuroscience’s At-Home Depression Treatment

Flow Neuroscience recently claimed that the U.S. Food and Drug Administration (FDA) has cleared its innovative Flow device, a home-use brain stimulator for treating major depressive disorder (MDD) in adults with moderate to severe symptoms.

This approval paves the way for U.S. doctors to recommend this drug-free option either alone or alongside other therapies, marking a historic shift in accessible mental health care.

The Growing Depression Crisis

Over 20 million American adults battle depression, with cases surging 60 percent in the past decade. About one-third don’t respond to medications, and many quit due to harsh side effects like weight gain, sexual issues, and emotional numbness.

How Flow Works

The device employs transcranial direct current stimulation (tDCS), a technique supported by 25+ years of research across 9,000+ studies for depression, stroke rehab, and pain relief.

Flow delivers mild electrical pulses to the prefrontal cortex, a brain region key to mood and stress that’s often sluggish in depressed individuals.

CEO Erin Lee emphasized, “Our goal is to deliver affordable, side-effect-light tech therapies to millions sidelined by depression. This FDA nod is a game-changer, bridging pharma reliance to scalable home solutions.”

Groundbreaking Clinical Evidence

Flow’s pivotal randomized trial, published in Nature Medicine, was the largest ever for remote tDCS. Over 10 weeks, the FL-100 device slashed symptoms in as little as three weeks, with 58% of users reaching remission—two to three times better than placebo. It shone even for those on meds or therapy, mimicking everyday use. Real-world data shows 77 percent improvement in weeks, per Chief Medical Officer Dr. Kultar Garcha.

Co-founder Daniel Månsson added, “Six years of European success, with 55,000+ users including UK NHS patients, back this. U.S. rollout starts Q2 2026.”

Future Plans and Availability

Flow snagged FDA Breakthrough Device status in 2022 and eyes expansions to brain injuries, addiction, and sleep issues.

It requires a prescription for ages 18+, downloadable on iOS/Android soon. Mild side effects like skin irritation or headaches are typical; avoid reusing pads to prevent burns.

To learn more about products from Flow, visit their official website.

Tags: Flow
Previous Post

GE Lighting Unveils Light + Form Decorative Bulbs, Updated Reveal Series

Next Post

Ultrahuman Home Adds Ambient Sleep & Respiratory Tracking; Snore/Cough Analysis

Jude Chukwuemeka

Jude Chukwuemeka

Jude Chukwuemeka is a passionate writer and online blogger who explores diverse topics with insight and creativity. On AndroidGuys.com he enjoys crafting engaging content that informs and inspires readers around the world.

Related Posts

No Content Available
No Result
View All Result
  • Home
  • Featured
  • The Best
  • News
  • Reviews
  • Promoted